Theraclion has received de novo marketing authorisation from the US Food and Drug Administration (FDA) for Sonovein, a platform that uses high-intensity focused ultrasound (HIFU) to treat varicose veins without an incision or an intravascular catheter, the company announced.
According to the company, the US FDA granted the authorisation 4 November, 2026. In the US, Sonovein is intended for the coagulation of blood vessels in patients with superficial vein reflux in the great saphenous vein (GSV) segments. Superficial venous reflux, most often involving the GSV, is the main cause of varicose veins. Theraclion says Sonovein is the first and only US FDA-authorised HIFU platform for non-invasive varicose vein treatment.
The authorisation is supported by the VEINRESET pivotal study, which enrolled 70 patients at four centers in the USA and Europe. According to the company, the study met its primary endpoint, with a GSV occlusion rate of 96.8% at 12 months. Theraclion reported no serious or unanticipated adverse events and one mild adverse event.
“This authorisation marks the culmination of years of clinical and regulatory work and opens a defining new chapter for Theraclion,” said Martin Deterre, the company’s chief executive officer. “Sonovein enables entirely non-invasive vein treatment, without incisions or catheters.”
Deterre added that the authorisation is the starting point for US commercialisation. “Our priority is to establish successful treatment centers, build sustained adoption and deliver growth,” he said.
Theraclion has incorporated a US subsidiary, Sonovein Inc., and says its launch preparations are already in place. A dedicated Category III current procedural terminology (CPT) code for non-invasive HIFU vein procedures has been active since 1 October, 2026 enabling standardised reporting and tracking. The company describes the code as an initial step toward developing coverage and payment pathways.
The initial US roll out will focus on establishing reference treatment centers through physician training, clinical onboarding, and technical and service support. Theraclion says sustained use at these sites will form the basis for wider adoption.











